Articles related to SICKLE CELL DISEASE (SCD)

The comparative modeling analysis of gene therapy for sickle cell disease underscores its potential cost-effectiveness and value in enhancing patient quality of life. With estimated ICERs significantly varying under different perspectives, the findings advocate for a nuanced approach to assessing novel therapies within the broader healthcare landscape.

Gain actionable insights into the diagnosis and management of nonmalignant blood disorders at Mayo Clinic’s Classical Hematology 2023 conference. Elevate your practice with evidence-based strategies from leading experts.

This study provides new insights into using electronic health records as an efficient tool for predicting survival outcomes in SCA treatment, highlighting the significant role of hydroxyurea in lowering mortality rates.

Learn how CRISPR-Cas9 gene editing holds the promise of elevating fetal hemoglobin levels and significantly reducing sickle cell disease manifestations. Explore the study’s findings to consider this potential game-changer for your practice.

The FDA’s recent decision allows Fulcrum Therapeutics to continue its Phase 1b trial of FTX-6058, an oral therapy for SCD. The trial aims to explore the drug’s potential in increasing fetal hemoglobin levels, offering a new avenue for treatment.

Home-based therapies are emerging as a viable solution to the challenges faced by global healthcare systems, particularly for conditions like sickle cell disease. Dive deeper into the research and implications for patient care.